Forma Therapeutics, Inc.

This study tests a new daily pill, etavopivat, in 27 children aged 12–16 with sickle cell disease who are at higher risk for a first stroke. The medicine aims to improve blood flow in the brain, measured by ultrasound, over one year. Participants may already be taking hydroxyurea…

This study tests a once-daily pill called etavopivat in children aged 6 months to 18 years with sickle cell disease. The main goals are to check the medicine's safety and how it moves through the body. Participants take the pill every day for 96 weeks and have regular check-ups. …